Altimmune to Participate in the Citizens Life Sciences Conference

Group 1 - Altimmune, Inc. will participate in a fireside chat at the Citizens Life Sciences Conference on May 7, 2025, at 9:30 a.m. EDT [1] - The session will be available via webcast on the Altimmune website [1] - Altimmune is a late clinical-stage biopharmaceutical company focused on next-generation peptide-based therapeutics [2] Group 2 - The company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist aimed at treating obesity, MASH, alcohol use disorder, and alcohol-related liver disease [2]